This site is intended for healthcare professionals
Improving treatment options for childhood psoriasis

Mia's treatment

Read time: 55 mins
Published:4th Jul 2020
Did you know that the majority of topical and systemic treatments for psoriasis are not approved for use in paediatric patients? Fortunately, guidelines for treating childhood psoriasis are available to guide physicians.

How has Mia been treated in the past?

Mia has tried many treatments over the six years that she suffered from moderate-to-severe psoriasis, but none so far have had any long-term benefits. 

In this animation, Mia, her parents and her doctor thoroughly review her treatment history and discuss what has worked and what has caused unacceptable side effects.

Such discussions are invaluable in the shared decision-making treatment approach. As Mia is approaching adolescence, a critical point in the development of emotional and psychosocial well-being25, her parents and doctor are keen to keep trying new treatment options which could work for Mia.

Find out what treatments could be available for Mia soon

Continue on to find out what paediatric psoriasis clinical guidelines recommend and the latest data for approved treatments.

Paediatric psoriasis treatment guidelines were previously limited

Societies, associations and institutes develop clinical guidelines for the treatment and management of psoriasis at local, national, and international levels.

International guidelines for psoriasis in adults have been shown to be relatively consistent concerning older biologic therapies, but differing when it came to switching biologics, monitoring outcomes and combining therapies1.

Register free for full access to medthority.com

A number of treatments are approved or recommended for use in children with moderate-to-severe psoriasis

Psoriasis treatment in adults is largely based on disease severity determined by the % of body surface (BSA) affected2:

  • <3% BSA considered mild
  • 3–10% BSA considered moderate
  • >10% BSA considered severe
Register free for full access to medthority.com

Current treatments are not always effective in the real world

The efficacy of biologics for childhood psoriasis and effect on quality of life (QoL) is certainly impressive from the clinical trial data but could this data be considered a ‘best-case scenario’ given that patients with more severe disease and/or comorbidities may not have been eligible to be included in the clinical trials? How does this compare with real-world data?

Register free for full access to medthority.com

References

  1. Stiff KM, Glines KR, Porter CL, Cline A, Feldman SR. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. Expert Review of Clinical Pharmacology. 2018;11(12):1209–1218.
  2. Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201.
Register free for full access to medthority.com

Welcome:

Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.